Enhanced vasodilatory responses to milrinone in catecholamine-precontracted small pulmonary arteries

Anesthesia and Analgesia

Volumn 98, Issue 6, 2004, Pages 1618-1622

  Jhaveri, Rajiv ^a   Kim, Soonyul ^a   White, A Ron ^a   Burke, Sean ^a   Berkowitz, Dan E ^a,b   Nyhan, Daniel ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCERYL TRINITRATE; MILRINONE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; HEART DISEASE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FUNCTION; LUNG VASCULAR RESISTANCE; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY ARTERY; SWINE; VASODILATATION;

EID: 2442649261     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000115781.69209.59     Document Type: Article

References (16)

1. Siostrzonek P, Koreny M, Delle-Karth G, et al. Milrinone therapy in catecholamine-dependent critically ill patients with heart failure. Acta Anaesthesiol Scand 2000;44:403-9.
2. Ono K, Tareen FM, Yoshida A, Noma A. Synergistic action of cyclic GMP on catecholamine-induced chloride current in guinea-pig ventricular cells. J Physiol 1992;453:647-61.
3. Bohm M, Diet F, Kemkes B, Erdmann E. Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart. Klin Wochenschr 1988;66:957-62.
4. Moraes DL, Colucci WS, Givertz MD. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000; 102:1718-23.
5. Feelisch M. Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur Heart J 1993;14: 123-32.
6. Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med 1991;154: 51-62.
7. Fung HL. Clinical pharmacology of organic nitrates. Am J Cardiol 1993;72:9C-13; discussion 14C-5.
8. Schmitz W, von der Leyen H, Meyer W, et al. Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 1989;14:S11-4.
9. Honerjager P, Nawrath H. Pharmacology of bipyridine phosphodiesterase III inhibitors. Eur J Anaesthesiol 1992;(Suppl 5): 7-14.
10. Honerjager P. Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J 1991;121:1939-44.
11. Hopkins PM, O'Beirne HA. Smooth muscle. In: Hemmings HC, Hopkins PM, eds. Foundations of anesthesia: basic and clinical sciences. London: Mosby, 2000:353-60.
12. Erdmann E. The effect of positive inotropes on the failing human myocardium. Cardiology 1997;88:7-11.
13. Orime Y, Shiono M, Hata H, et al. Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 1998;46:803-9.
14. Wagner RS, Smith CJ, Taylor AM, Rhoades RA. Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 1997;282: 1650-7.
15. Bailey JM, Levy JH, Kikura M, et al. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology 1994;81:616-22.
16. Boels P, Deutsch J, Gao B, Haworth SG. Maturation of the response to bradykinin in resistance and conduit pulmonary arteries. Cardiovasc Res 1999;44:416-28.